Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer

AbstractPurpose of ReviewThe treatment options for high-risk non-muscle invasive bladder cancer (NMIBC), particularly following BCG, remain limited. We highlight recent, promising therapies for high-risk NMIBC.Recent FindingsSeveral therapies utilizing different mechanisms of action have demonstrated favorable results in the BCG-na ïve and BCG-unresponsive settings. These treatments include intravenous and intravesical immunotherapy, viral- and bacterial-based intravesical therapies, combination intravesical chemotherapy regimens, and novel intravesical chemotherapy administration. Overall, the efficacy and tolerability of em erging treatments for NMIBC appear promising and provide potential alternatives to radical cystectomy.SummaryAs the landscape of managing BCG-unresponsive disease evolves, clinical trials will explore future options and determine effective alternatives.
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research